Results 271 to 280 of about 117,898 (292)

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications

Nature Medicine, 2006
Ingo Roeder, Ingmar Glauche, Andreas Hochhaus   +2 more
exaly  

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

Science, 2004
Charles L Sawyers
exaly  

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Lancet, The, 2006
George D Demetri, Jaap Verweij, Grant Mcarthur   +2 more
exaly  

Imatinib

Reactions Weekly, 2017
openaire   +2 more sources

Imatinib and beyond—exploring the full potential of targeted therapy for CML

Nature Reviews Clinical Oncology, 2009
Hagop M Kantarjian, Jorge Cortes
exaly  

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

Cancer Cell, 2012
Ling Li, Zhiqiang Wang, Tessa L Holyoake
exaly  

Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria

Journal of Clinical Oncology, 2007
Shreyaskumar R Patel
exaly  

Imatinib

Reactions Weekly, 2015
openaire   +2 more sources

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2009
Ronald P Dematteo, Karla V Ballman, Robert G Maki   +2 more
exaly  

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Lancet Oncology, The, 2010
François Guilhot, Laurence Legros, Gabriel Etienne   +2 more
exaly